Search
Twelve students have successfully defended their dissertations and will receive their PhD degrees at Commencement on May 14.
Learn about a clinical trial at Memorial Sloan Kettering that is using plasma donated by MSK employees who have recovered from COVID-19.
Hepatic arterial infusion chemotherapy given to colorectal cancer patients with liver metastases extends their survival by almost two years, according to a large retrospective study from Memorial Sloan Kettering recently published in the JCO.
Annually, GSK awards fellowships to two second-year students and six first-year students based on academic achievement in different elements of the curriculum.
To help some patients to overcome leukemia, MSK doctors are calling upon patients’ microbiomes — the vast ecosystems of microorganisms that live within us, especially the gut. These microbes appear to help some patients recover from bone marrow and stem cell transplants.
Seven GSK PhD students were awarded nine competitive fellowships from prestigious external agencies such as the National Cancer Institute (NCI) and National Science Foundation (NSF).
About a third of patients with metastatic breast cancer don’t respond well to the standard anti-estrogen therapies; to find ways to better treat those patients, Memorial Sloan Kettering Cancer Center is studying three new selective estrogen receptor down-regulators (SERDs) in clinical trials.
MSK researchers continued to make strides against cancer in 2024. Learn about some of their top discoveries.
Learn about larotrectinib, the first cancer drug to be FDA approved for adult and pediatric patients at the same time.
This study demonstrates how clonal hematopoiesis (CH)–derived mutations could lead to erroneous reporting and treatment recommendations when tumor-only sequencing is employed. If data about the blood are not part of test results, mutations present in the blood may be misread as mutations in the tumor, which can potentially affect the therapies patients receive. Data presented at the annual meeting of the American Society of Clinical Oncology by Ahmet Zehir, PhD, Director of Clinical Bioinformatics at Memorial Sloan Kettering Cancer Center (MSK) was simultaneously published in JAMA Oncology on June 5.